Glofitamab (Columvi, Roche) in combination with gemcitabine and oxaliplatin is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT)'.
The dosage schedule is available in the summary of product characteristics for glofitamab.
The list price for glofitamab is £687 per 2.5‑mg vial and £2,748 per 10‑mg vial (excluding VAT, BNF online, accessed July 2025).
The list price for gemcitabine is £14 per 200‑mg vial of powder for solution for infusion and £25 per 1,000‑mg vial of powder for solution for infusion (excluding VAT, BNF online, accessed July 2025).
The list price for oxaliplatin is £147.82 per 50 mg (10 ml) vial of concentrate for solution for infusion and £295.63 per 100 mg (20 ml) vial of concentrate for solution for infusion (excluding VAT, BNF online, accessed July 2025).
The company has a commercial arrangement. This makes glofitamab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions for Roche guidance is published on Roche's 'about sustainability' webpage.